Literature DB >> 10506723

Significantly lower incidence of cancer among patients with Huntington disease: An apoptotic effect of an expanded polyglutamine tract?

S A Sørensen1, K Fenger, J H Olsen.   

Abstract

BACKGROUND: The authors of this study have previously observed that cancer is rarely reported on the death certificates of patients with Huntington disease. This study was undertaken to investigate whether this disorder is associated with a lower incidence of cancer.
METHODS: A total of 694 patients with Huntington disease who had survived at least to age 45 years during the period 1943-1993, and 695 individuals at risk and at least age 55 years during the same period, were selected from the Danish Huntington Disease Registry. The occurrence of cancer was determined from the files of the Danish Cancer Registry and compared with national incidence rates for various categories of tumors.
RESULTS: The overall incidence of cancer was significantly lower among patients with Huntington disease, but not among their healthy relatives. The standardized incidence ratio for the Huntington patients was 0.6 with a 95% confidence interval of 0.5-0.8. The lower incidence was seen for cancers of all major tissues and organs except the buccal cavity and the pharynx.
CONCLUSIONS: The lower incidence of cancer among patients with Huntington disease seems to be related to intrinsic biologic factors. One explanation may be that the modified protein, huntingtin, encountered in Huntington disease protects against cancer by inducing or increasing the rate of naturally occurring programmed cell death in preneoplastic cells. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506723

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

3.  Comment on Eskenazi et al.

Authors:  Roger L Albin
Journal:  Med Hypotheses       Date:  2008-03-10       Impact factor: 1.538

Review 4.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.

Authors:  Rafael Tabarés-Seisdedos; John L Rubenstein
Journal:  Nat Rev Neurosci       Date:  2013-04       Impact factor: 34.870

5.  CAG repeat size in Huntingtin alleles is associated with cancer prognosis.

Authors:  Morgane Sonia Thion; Sophie Tézenas du Montcel; Jean-Louis Golmard; Sophie Vacher; Laure Barjhoux; Valérie Sornin; Cécile Cazeneuve; Ivan Bièche; Olga Sinilnikova; Dominique Stoppa-Lyonnet; Alexandra Durr; Sandrine Humbert
Journal:  Eur J Hum Genet       Date:  2016-03-16       Impact factor: 4.246

6.  Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells.

Authors:  Andrea E Murmann; Quan Q Gao; William E Putzbach; Monal Patel; Elizabeth T Bartom; Calvin Y Law; Bryan Bridgeman; Siquan Chen; Kaylin M McMahon; C Shad Thaxton; Marcus E Peter
Journal:  EMBO Rep       Date:  2018-02-12       Impact factor: 8.807

7.  Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival.

Authors:  Dinesh S Rao; Teresa S Hyun; Priti D Kumar; Ikuko F Mizukami; Mark A Rubin; Peter C Lucas; Martin G Sanda; Theodora S Ross
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 8.  Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Miles R Bryan; Aaron B Bowman
Journal:  Adv Neurobiol       Date:  2017

Review 9.  Biological functions and potential therapeutic applications of huntingtin-associated protein 1: progress and prospects.

Authors:  X Zhao; A Chen; Z Wang; Xiao-Han Xu; Y Tao
Journal:  Clin Transl Oncol       Date:  2021-09-26       Impact factor: 3.405

10.  Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort.

Authors:  Filipe Brogueira Rodrigues; Daisy Abreu; Joana Damásio; Nilza Goncalves; Leonor Correia-Guedes; Miguel Coelho; Joaquim J Ferreira
Journal:  Mov Disord Clin Pract       Date:  2017-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.